VVOS Vivos Therapeutics Inc
Price (delayed)
$3
Market cap
$10.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.03
Enterprise value
$5.07M
Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that
Highlights
The company's quick ratio has surged by 182% QoQ and by 116% YoY
VVOS's EPS has soared by 60% YoY and by 36% from the previous quarter
The gross profit has declined by 10% year-on-year but it is up by 7% since the previous quarter
Vivos Therapeutics's revenue has decreased by 9% YoY but it has increased by 4.9% from the previous quarter
Key stats
What are the main financial stats of VVOS
Market
Valuations
Earnings
Shares outstanding
3.4M
Market cap
$10.2M
Enterprise value
$5.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.36
Revenue
$14.02M
EBIT
-$12.05M
EBITDA
-$11.46M
Free cash flow
-$11.64M
Per share
Balance sheet
Liquidity
EPS
-$7.03
Free cash flow per share
-$3.61
Book value per share
$1.97
Revenue per share
$4.34
TBVPS
$3.9
Total assets
$15.84M
Total liabilities
$9.5M
Debt
$1.76M
Equity
$6.35M
Working capital
$1.21M
Debt to equity
0.28
Current ratio
1.18
Quick ratio
1.1
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-81.7%
Gross margin
60.1%
Net margin
-85.9%
Operating margin
-95.2%
Return on assets
-98.9%
Return on equity
-652.3%
Return on invested capital
-2,298.7%
Return on capital employed
-130.9%
Return on sales
-85.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VVOS stock price
How has the Vivos Therapeutics stock price performed over time
Intraday
1.69%
1 week
1.35%
1 month
28.76%
1 year
-51.06%
YTD
-75.88%
QTD
35.14%
Financial performance
How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$14.02M
Gross profit
$8.42M
Operating income
-$13.35M
Net income
-$12.05M
Gross margin
60.1%
Net margin
-85.9%
Vivos Therapeutics's operating income has increased by 36% YoY and by 16% from the previous quarter
The net income has grown by 36% YoY and by 23% from the previous quarter
The company's operating margin rose by 30% YoY and by 20% QoQ
Vivos Therapeutics's net margin has increased by 29% YoY and by 27% from the previous quarter
Growth
What is Vivos Therapeutics's growth rate over time
Valuation
What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
1.53
P/S
0.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.36
VVOS's EPS has soared by 60% YoY and by 36% from the previous quarter
The price to book (P/B) is 97% lower than the last 4 quarters average of 46.3
Vivos Therapeutics's revenue has decreased by 9% YoY but it has increased by 4.9% from the previous quarter
VVOS's P/S is 2.9% below its last 4 quarters average of 0.7
Efficiency
How efficient is Vivos Therapeutics business performance
The return on invested capital has dropped by 190% year-on-year but it is up by 43% since the previous quarter
The company's return on equity has shrunk by 107% YoY but it has surged by 67% QoQ
VVOS's ROS is up by 29% YoY and by 27% from the previous quarter
The company's return on assets rose by 26% QoQ and by 17% YoY
Dividends
What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VVOS.
Financial health
How did Vivos Therapeutics financials performed over time
VVOS's total assets is 67% higher than its total liabilities
The company's quick ratio has surged by 182% QoQ and by 116% YoY
The current ratio has surged by 162% since the previous quarter and by 87% year-on-year
Vivos Therapeutics's debt is 72% less than its equity
VVOS's debt to equity has dropped by 91% since the previous quarter and by 73% year-on-year
Vivos Therapeutics's debt has decreased by 20% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.